Nonsteroidal tissue-selective androgen receptor modulators

Nuclear Receptors as Drug Targets

Volumn 39, Issue , 2008, Pages 249-304

  Mohler, Michael L ^a   Bohl, Casey E ^a   Narayanan, Ramesh ^a   He, Yali ^a   Hwang, Dong Jin ^a   Dalton, James T ^a   Miller, Duane D ^a  

^a GTx Inc   (United States)

Author keywords

Anabolic agent; Androgen receptor; Cancer cachexia; Nonsteroidal androgen; Osteoporosis; Sarcopenia; SARM; Selective androgen receptor modulator

Indexed keywords

DISEASES;

ANABOLIC AGENTS; ANDROGEN RECEPTORS; CANCER CACHEXIA; NONSTEROIDAL ANDROGEN; OSTEOPOROSIS; SARCOPENIA; SARM;

MODULATORS;

EID: 85001595153     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527623297.ch8     Document Type: Chapter

References (252)

1. Mooradian, A.D., Morley, J.E. and Korenman, S.G. (1987) Biological actions of androgens. Endocrine Reviews, 8, 1-28.
2. Keller, E.T., Ershler, W.B. and Chang, C. (1996) The androgen receptor: a mediator of diverse responses. Frontiers in Bioscience: a Journal and Virtual Library, 1, 59-71.
3. Lubahn, D.B., Joseph, D.R., Sar, M., Tan, J., Higgs, H.N., Larson, R.E., French, F.S. and Wilson, E.M. (1988) The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Molecular Endocrinology, 2, 1265-1275.
4. Matias, P.M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., Basler, S., Schafer, M., Egner, U. and Carrondo, M.A. (2000) Structural evidence for ligand specificity in the binding domain of the human androgen receptor. Implications for pathogenic gene mutations. The Journal of Biological Chemistry, 275, 26164-26171.
5. Alen, P., Claessens, F., Verhoeven, G., Rombauts, W. and Peeters, B. (1999) The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Molecular and Cellular Biology, 19, 6085-6097.
6. Jenster, G., van der Korput, H.A., van Vroonhoven, C., van der Kwast, T.H., Trapman, J. and Brinkmann, A.O. (1991) Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Molecular Endocrinology, 5, 1396-1404.
7. Simental, J.A., Sar, M., Lane, M.V., French, F.S. and Wilson, E.M. (1991) Transcriptional activation and nuclear targeting signals of the human androgen receptor. The Journal of Biological Chemistry, 266, 510-518.
8. Ekena, K., Katzenellenbogen, J.A. and Katzenellenbogen, B.S. (1998) Determinants of ligand specificity of estrogen receptor-α: estrogen versus androgen discrimination. The Journal of Biological Chemistry, 273, 693-699.
9. Bledsoe, R.K., Montana, V.G., Stanley, T.B., Delves, C.J., Apolito, C.J., McKee, D.D., Consler, T.G., Parks, D.J., Stewart, E.L., Willson, T.M., Lambert, M.H., Moore, J.T., Pearce, K.H. and Xu, H.E. (2002) Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell, 110, 93-105.
10. Bohl, C.E., Gao, W., Miller, D.D., Bell, C.E. and Dalton, J.T. (2005) Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 102, 6201-6206.
11. Tanenbaum, D.M., Wang, Y., Williams, S.P. and Sigler, P.B. (1998) Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. Proceedings of the National Academy of Sciences of the United States of America, 95, 5998-6003.
12. Diver, M.J. (2006) Analytical and physiological factors affecting the interpretation of serum testosterone concentration in men. Annals of Clinical Biochemistry, 43, 3-12.
13. Veldscholte, J., Berrevoets, C.A., Zegers, N.D., van der Kwast, T.H., Grootegoed, J.A. and Mulder, E. (1992) Hormoneinduced dissociation of the androgen receptor-heat-shock protein complex:use of a new monoclonal antibody to distinguish transformed from nontransformed receptors. Biochemistry, 31, 7422-7430.
14. He, B., Minges, J.T., Lee, L.W. and Wilson, E.M. (2002) The FXXLF motif mediates androgen receptor-specific interactions with coregulators. The Journal of Biological Chemistry, 277, 10226-10235.
15. 2-terminal and carboxyl-terminal interaction in the human androgen receptor. Molecular Genetics and Metabolism, 75, 293-298.
16. Hur, E., Pfaff, S.J., Payne, E.S., Gron, H., Buehrer, B.M. and Fletterick, R.J. (2004) Recognition and accommodation at the androgen receptor coactivator binding interface. PLoS Biology, 2, e274.
17. Norman, A.W., Mizwicki, M.T. and Norman, D.P. (2004) Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nature Reviews Drug Discovery, 3, 27-41.
18. Wilson, J.D., Harrod, M.J., Goldstein, J.L., Hemsell, D.L. and MacDonald, P.C. (1974) Familial incomplete male pseudohermaphroditism, type 1. Evidence for androgen resistance and variable clinical manifestations in a family with the Reifenstein syndrome. The New England Journal of Medicine, 290, 1097-1103.
19. Brinkmann, A.O. (2001) Molecular basis of androgen insensitivity. Molecular and Cellular Endocrinology, 179, 105-109.
20. Gottlieb, B., Pinsky, L., Beitel, L.K. and Trifiro, M. (1999) Androgen insensitivity. American Journal of Medical Genetics, 89, 210-217.
21. Scher, H.I. and Sawyers, C.L. (2005) Biology of progressive, castrationresistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. Journal of Clinical Oncology, 23, 8253-8261.
22. Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., Kamoto, T. and Ogawa, O. (2005) Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamidetreated patient. Cancer Research, 65, 9611-9616.
23. Gelmann, E.P. (2002) Molecular biology of the androgen receptor. Journal of Clinical Oncology, 20, 3001-3015.
24. Gottlieb, B., Beitel, L.K., Wu, J.H. and Trifiro, M. (2004) The androgens receptor gene mutations database (ARDB): 2004 update. Human Mutation, 23, 527-533.
25. Culig, Z., Hobisch, A., Cronauer, M.V., Cato, A.C., Hittmair, A., Radmayr, C., Eberle, J., Bartsch, G. and Klocker, H. (1993) Mutant androgens receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Molecular Endocrinology, 7, 1541-1550.
26. Elo, J.P., Kvist, L., Leinonen, K., Isomaa, V., Henttu, P., Lukkarinen, O. and Vihko, P. (1995) Mutated human androgens receptor gene detected in a prostatic cancer patient is also activated by estradiol. The Journal of Clinical Endocrinology and Metabolism, 80, 3494-3500.
27. Steketee, K., Timmerman, L., Ziel-van der Made, A.C., Doesburg, P., Brinkmann, A.O. and Trapman, J. (2002) Broadened ligand responsiveness of androgens receptor mutants obtained by random amino acid substitution of H874 and mutation hot spot T877 in prostate cancer. International Journal of Cancer, 100, 309-317.
28. Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M. and Miyamoto, M. (2003) Novel mutations of androgens receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Research, 63, 149-153.
29. Brooks, B.P. and Fischbeck, K.H. (1995) Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Trends in Neurosciences, 18, 459-461.
30. Giovannucci, E., Stampfer, M.J., Krithivas, K., Brown, M., Dahl, D., Brufsky, A., Talcott, J., Hennekens, C.H. and Kantoff, P.W. (1997) The CAG repeat within the androgens receptor gene and its relationship to prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 94, 3320-3323.
31. Ferro, P., Catalano, M.G., Dell'Eva, R., Fortunati, N. and Pfeffer, U. (2002) The androgens receptor CAG repeat:a modifier of carcinogenesis? Molecular and Cellular Endocrinology, 193, 109-120.
32. Bhasin, S. and Bremner, W.J. (1997) Clinical review 85: emerging issues in androgens replacement therapy. The Journal of Clinical Endocrinology and Metabolism, 82, 3-8.
33. Gruenewald, D.A. and Matsumoto, A.M. (2003) Testosterone supplementation therapy for older men: potential benefits and risks. Journal of the American Geriatrics Society, 51, 101-115. discussion 115.
34. Wu, F.C. (1992) Testicular steroidogenesis and androgens use and abuse. Baillieres Clinical Endocrinology and Metabolism, 6, 373-403.
35. Gao, W., Bohl, C.E. and Dalton, J.T. (2005) Chemistry and structural biology of androgens receptor. Chemical Reviews, 105, 3352-3370.
36. Heywood, R., Chesterman, H., Ball, S.A. and Wadsworth, P.F. (1977) Toxicity of methyl testosterone in the beagle dog. Toxicology, 7, 357-365.
37. Ishak, K.G. and Zimmerman, H.J. (1987) Hepatotoxic effects of the anabolic/androgensic steroids. Seminars in Liver Disease, 7, 230-236.
38. Velazquez, E. and Bellabarba Arata, G. (1998) Testosterone replacement therapy. Archives of Andrology, 41, 79-90.
39. Drillich, A. and Davis, S.R. (2007) Androgen therapy in women: what we think we know. Experimental Gerontology, 42, 457-462.
40. Swerdloff, R.S., Wang, C. and Bhasin, S. (1992) Developments in the control of testicular function. Baillieres Clinical Endocrinology and Metabolism, 6, 451-483.
41. Rodway, R.G. and Galbraith, H. (1979) Effects of anabolic steroids on hepatic enzymes of amino acid catabolism. Hormone and Metabolic Research, 11, 489-490.
42. Wilson, J.D., Aiman, J. and MacDonald, P.C. (1980) The pathogenesis of gynecomastia. Advanced Internal Medicine, 25, 1-32.
43. Neri, R., Florance, K., Koziol, P. and Van Cleave, S. (1972) A biological profile of a nonsteroidal antiandrogen, SCH 13521 (4'-nitro-3'-trifluoromethylisobutyranilide). Endocrinology, 91, 427-437.
44. Neri, R., Peets, E. and Watnick, A. (1979) Anti-androgensicity of flutamide and its metabolite Sch 16423. Biochemical Society Transactions, 7, 565-569.
45. Neri, R.O. and Peets, E.A. (1975) Biological aspects of antiandrogens. Journal of Steroid Biochemistry, 6, 815-819.
46. Harris, M.G., Coleman, S.G., Faulds, D. and Chrisp, P. (1993) Nilutamide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer. Drugs Aging, 3, 9-25.
47. Moguilewsky, M., Bertagna, C. and Hucher, M. (1987) Pharmacological and clinical studies of the antiandrogens Anandron. Journal of Steroid Biochemistry, 27, 871-875.
48. Raynaud, J.P., Bonne, C., Moguilewsky, M., Lefebvre, F.A., Belanger, A. and Labrie, F. (1984) The pure antiandrogens RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review. Prostate, 5, 299-311.
49. Furr, B.J., Valcaccia, B., Curry, B., Woodburn, J.R., Chesterson, G. and Tucker, H. (1987) ICI 176, 334: a novel non-steroidal, peripherally selective antiandrogens. The Journal of Endocrinology, 113, R7-R9.
50. Kaisary, A.V. (1994) Current clinical studies with a new nonsteroidal antiandrogens, Casodex. Prostate. Supplement, 5, 27-33.
51. Lunglmayr, G. (1995) Efficacy and tolerability of Casodex in patients with advanced prostate cancer. International Casodex Study Group, Anti-Cancer Drugs, 6, 508-513.
52. Teutsch, G., Goubet, F., Battmann, T., Bonfils, A., Bouchoux, F., Cerede, E., Gofflo, D., Gaillard-Kelly, M. and Philibert, D. (1994) Non-steroidal antiandrogens: synthesis and biological profile of high-affinity ligands for the androgens receptor. The Journal of Steroid Biochemistry and Molecular Biology, 48, 111-119.
53. Peets, E.A., Henson, M.F. and Neri, R. (1974) On the mechanism of the antiandrogensic action of flutamide (α-α-α-trifluoro-2-methyl-4'-nitro-mpropionotoluidide) in the rat. Endocrinology, 94, 532-540.
54. Moguilewsky, M., Fiet, J., Tournemine, C. and Raynaud, J.P. (1986) Pharmacology of an antiandrogens, anandron, used as an adjuvant therapy in the treatment of prostate cancer. Journal of Steroid Biochemistry, 24, 139-146.
55. Creaven, P.J., Pendyala, L. and Tremblay, D. (1991) Pharmacokinetics and metabolism of nilutamide. Urology, 37 (2 Suppl), 13-19.
56. Berson, A., Wolf, C., Berger, V., Fau, D., Chachaty, C., Fromenty, B. and Pessayre, D. (1991) Generation of free radicals during the reductive metabolism of the nitroaromatic compound, nilutamide. The Journal of Pharmacology and Experimental Therapeutics, 257, 714-719.
57. Fau, D., Berson, A., Eugene, D., Fromenty, B., Fisch, C. and Pessayre, D. (1992) Mechanism for the hepatotoxicity of the antiandrogens, nilutamide. Evidence suggesting that redox cycling of this nitroaromatic drug leads to oxidative stress in isolated hepatocytes. The Journal of Pharmacology and Experimental Therapeutics, 263, 69-77.
58. Kennealey, G.T. and Furr, B.J. (1991) Use of the nonsteroidal anti-androgens Casodex in advanced prostatic carcinoma. Urologic Clinics of North America, 18, 99-110.
59. Cockshott, I.D., Cooper, K.J., Sweetmore, D.S., Blacklock, N.J. and Denis, L. (1990) The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. European Urology, 18 (Suppl 3), 10-17.
60. Furr, B.J. (1989) .Casodex. (ICI 176, 334) - a new, pure, peripherally-selective antiandrogens:preclinical studies. Hormone Research, 32 (Suppl 1), 69-76.
61. Hershberger, L.G., Shipley, E.G. and Meyer, R.K. (1953) Myotrophic activity of 19-nortestosterone and other steroids determined by modified levator ani muscle method. Proceedings of the Society for Experimental Biology and Medicine, 83, 175-180.
62. Cockshott, I.D. (2004) Bicalutamide:clinical pharmacokinetics and metabolism. Clinical Pharmacokinetics, 43, 855-878.
63. Salvati, M.E., Balog, A., Wei, D.D., Pickering, D., Attar, R.M., Geng, J., Rizzo, C.A., Hunt, J.T., Gottardis, M.M., Weinmann, R. and Martinez, R. (2005) Identification of a novel class of androgens receptor antagonists based on the bicyclic-1H-isoindole-1,3(2H)-dione nucleus. Bioorganic & Medicinal Chemistry Letters, 15, 389-393.
64. Salvati, M.E., Balog, A., Shan, W., Wei, D.D., Pickering, D., Attar, R.M., Geng, J., Rizzo, C.A., Gottardis, M.M., Weinmann, R., Krystek, S.R., Sack, J., An, Y. and Kish, K. (2005) Structure based approach to the design of bicyclic-1H-isoindole-1,3(2H)-dione based androgens receptor antagonists. Bioorganic & Medicinal Chemistry Letters, 15, 271-276.
65. Ng, R.A., Guan, J., Alford, V.C., Jr. Lanter, J.C., Allan, G.F., Sbriscia, T., Linton, O., Lundeen, S.G. and Sui, Z. (2007) Synthesis and SAR of potent and selective androgens receptor antagonists: 5, 6-dichloro-benzimidazole derivatives. Bioorganic & Medicinal Chemistry Letters, 17, 784-788.
66. Lanter, J.C., Fiordeliso, J.J., Jiang, W., Allan, G.F., Lai, M.T., Linton, O., Hahn do, W., Lundeen, S.G. and Sui, Z. (2007) The discovery of a potent orally efficacious indole androgens receptor antagonist through in vivo screening. Bioorganic & Medicinal Chemistry Letters, 17, 123-126.
67. Pfizer, Inc., WO 2005/102990.
68. Pfizer, Inc., WO 2005/100305.
69. Pfizer, Inc., WO 2005/049574.
70. Endorecherche, Inc., US 6,933,321, (2005).
71. Endorecherche, Inc., WO 2006/133567.
72. McGinley, P.L. and Koh, J. (2007) Circumventing anti-androgens resistance by molecular design. Journal of the American Chemical Society, 129, 3822-3823.
73. Hwang, D.J., Yang, J., Xu, H., Rakov, I.M., Mohler, M.L., Dalton, J.T. and Miller, D.D. (2006) Arylisothiocyanato selective androgens receptor modulators (SARMs) for prostate cancer. Bioorganic and Medicinal Chemistry, 14, 6525-6538.
74. Kirkovsky, L., Mukherjee, A., Yin, D., Dalton, J.T. and Miller, D.D. (2000) Chiral nonsteroidal affinity ligands for the androgens receptor. 1. Bicalutamide analogues bearing electrophilic groups in the B aromatic ring. Journal of Medicinal Chemistry, 43, 581-590.
75. Yang, J., Bohl, C.E., Nair, V.A., Mustafa, S.M., Hong, S.S., Miller, D.D. and Dalton, J.T. (2006) Preclinical pharmacology of a nonsteroidal ligand for androgens receptor-mediated imaging of prostate cancer. The Journal of Pharmacology and Experimental Therapeutics, 317, 402-408.
76. Mukherjee, A., Kirkovsky, L.I., Kimura, Y., Marvel, M.M., Miller, D.D. and Dalton, J.T. (1999) Affinity labeling of the androgens receptor with nonsteroidal chemoaffinity ligands. Biochemical Pharmacology, 58, 1259-1267.
77. Mukherjee, A., Kirkovsky, L., Yao, X.T., Yates, R.C., Miller, D.D. and Dalton, J.T. (1996) Enantioselective binding of Casodex to the androgens receptor. Xenobiotica; The Fate of Foreign Compounds in Biological Systems, 26, 117-122.
78. Dalton, J.T., Mukherjee, A., Zhu, Z., Kirkovsky, L. and Miller, D.D. (1998) Discovery of nonsteroidal androgens. Biochemical and Biophysical Research Communications, 244, 1-4.
79. He, Y., Yin, D., Perera, M., Kirkovsky, L., Stourman, N., Li, W., Dalton, J.T. and Miller, D.D. (2002) Novel nonsteroidal ligands with high binding affinity and potent functional activity for the androgens receptor. European Journal of Medicinal Chemistry, 37, 619-634.
80. Edwards, J.P., West, S.J., Pooley, C.L., Marschke, K.B., Farmer, L.J. and Jones, T.K. (1998) New nonsteroidal androgens receptor modulators based on 4-(trifluoromethyl)-2(1H)-pyrrolidino[3,2-g] quinolinone. Bioorganic & Medicinal Chemistry Letters, 8, 745-750.
81. Higuchi, R.I., Edwards, J.P., Caferro, T.R., Ringgenberg, J.D., Kong, J.W., Hamann, L.G., Arienti, K.L., Marschke, K.B., Davis, R.L., Farmer, L.J. and Jones, T.K. (1999) 4-Alkyl-and 3,4-dialkyl-1,2,3,4-tetrahydro-8-pyridono[5,6-g]quinolines: potent, nonsteroidal androgens receptor agonists. Bioorganic &Medicinal Chemistry Letters, 9, 1335-1340.
82. Zhi, L., Tegley, C.M., Marschke, K.B. and Jones, T.K. (1999) Switching androgens receptor antagonists to agonists by modifying C-ring substituents on piperidino[3,2-g]quinolinone. Bioorganic & Medicinal Chemistry Letters, 9, 1009-1012.
83. Yin, D., He, Y., Perera, M.A., Hong, S.S., Marhefka, C., Stourman, N., Kirkovsky, L., Miller, D.D. and Dalton, J.T. (2003) Key structural features of nonsteroidal ligands for binding and activation of the androgens receptor. Molecular Pharmacology, 63, 211-223.
84. Marhefka, C.A., Moore, B.M., 2nd, Bishop, T.C., Kirkovsky, L., Mukherjee, A., Dalton, J.T. and Miller, D.D. (2001) Homology modeling using multiple molecular dynamics simulations and docking studies of the human androgens receptor ligand binding domain bound to testosterone and nonsteroidal ligands. Journal of Medicinal Chemistry, 44, 1729-1740.
85. Yin, D., Xu, H., He, Y., Kirkovsky, L.I., Miller, D.D. and Dalton, J.T. (2003) Pharmacology, pharmacokinetics, and metabolism of acetothiolutamide, a novel nonsteroidal agonist for the androgens receptor. The Journal of Pharmacology and Experimental Therapeutics, 304, 1323-1333.
86. Marhefka, C.A., Gao, W., Chung, K., Kim, J., He, Y., Yin, D., Bohl, C., Dalton, J.T. and Miller, D.D. (2004) Design, synthesis, and biological characterization of metabolically stable selective androgens receptor modulators. Journal of Medicinal Chemistry, 47, 993-998.
87. Yin, D., Gao, W., Kearbey, J.D., Xu, H., Chung, K., He, Y., Marhefka, C.A., Veverka, K.A., Miller, D.D. and Dalton, J.T. (2003) Pharmacodynamics of selective androgens receptor modulators. The Journal of Pharmacology and Experimental Therapeutics, 304, 1334-1340.
88. Kearbey, J.D., Wu, D., Gao, W., Miller, D.D. and Dalton, J.T. (2004) Pharmacokinetics of S-3-(4-acetylaminophenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethyl-phenyl)-propionamide in rats, a non-steroidal selective androgens receptor modulator. Xenobiotica; The Fate of Foreign Compounds in Biological Systems, 34, 273-280.
89. Bohl, C.E., Chang, C., Mohler, M.L., Chen, J., Miller, D.D., Swaan, P.W. and Dalton, J.T. (2004) A ligand-based approach to identify quantitative structure-activity relationships for the androgens receptor. Journal of Medicinal Chemistry, 47, 3765-3776.
90. Kim, J., Wu, D., Hwang, D.J., Miller, D.D. and Dalton, J.T. (2005) The para substituent of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-nitro-3-trifluoromethylphenyl)-propionamides is a major structural determinant of in vivo disposition and activity of selective androgens receptor modulators. The Journal of Pharmacology and Experimental Therapeutics, 315, 230-239.
91. Chen, J., Hwang, D.J., Chung, K., Bohl, C.E., Fisher, S.J., Miller, D.D. and Dalton, J.T. (2005) In vitro and in vivo structure-activity relationships of novel androgens receptor ligands with multiple substituents in the B-ring. Endocrinology, 146, 5444-5454.
92. Chen, J., Hwang, D.J., Bohl, C.E., Miller, D.D. and Dalton, J.T. (2005) A selective androgens receptor modulator for hormonal male contraception. The Journal of Pharmacology and Experimental Therapeutics, 312, 546-553.
93. Gao, W., Kearbey, J.D., Nair, V.A., Chung, K., Parlow, A.F., Miller, D.D. and Dalton, J.T. (2004) Comparison of the pharmacological effects of a novel selective androgens receptor modulator, the 5α-reductase inhibitor finasteride, and the antiandrogens hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia. Endocrinology, 145, 5420-5428.
94. Gao, W., Reiser, P.J., Coss, C.C., Phelps, M.A., Kearbey, J.D., Miller, D.D. and Dalton, J.T. (2005) Selective androgens receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats. Endocrinology, 146, 4887-4897.
95. Kearbey, J.D., Gao, W., Narayanan, R., Fisher, S.J., Wu, D., Miller, D.D. and Dalton, J.T. (2007) Selective androgens receptor modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharmaceutical Research, 24, 328-335.
96. Press release, 8 December 2006, GTx announces that ostarine achieved primary endpoint of lean body mass and a secondary endpoint of improved functional performance in a phase II clinical trial and reacquisition of full rights to GTx SARM program. http://www.gtxinc.com.
97. Press release, 7 September 2005, GTx, Inc. announces positive clinical results and development plans for ostarine. http://www.gtxinc.com.
98. Orion Corp., WO 2005/000794.
99. Heinonen, E. R&D pipeline of Orion Pharma - update of the progress of project. http://img.orion.fi/liitteet/200857.pdf.
100. Janssen Pharmaceutica NV, WO 2004/0113309.
101. Johnson & Johnson Co., US 2006/0211756.
102. Johnson & Johnson Co., US 2006/0063819.
103. Janssen Pharmaceutica NV, US 2005/245485.
104. Janssen Pharmaceutica NV, US 2005/250741.
105. Lanter, J.C., Fiordeliso, J.J., Allan, G.F., Musto, A., Hahn do, W. and Sui, Z. (2006) Abioisosteric approach to the discovery of indole carbinol androgens receptor ligands. Bioorganic & Medicinal Chemistry Letters, 16, 5646-5649.
106. SmithKline Beecham Corp., WO 2006/044707.
107. Merck & Co., Inc., WO 2007/016358.
108. Merck & Co., Inc., WO 2006/060108.
109. Merck & Co., Inc., US 2005/277681.
110. Merck & Co., Inc., WO 2004/041277.
111. Karo Bio AB, WO 2005/094810.
112. Edwards, J.P., Higuchi, R.I., Winn, D.T., Pooley, C.L., Caferro, T.R., Hamann, L.G., Zhi, L., Marschke, K.B., Goldman, M.E. and Jones, T.K. (1999) Nonsteroidal androgens receptor agonists based on 4-(trifluoromethyl)-2H-pyrano[3,2-g] quinolin-2-one. Bioorganic & Medicinal Chemistry Letters, 9, 1003-1008.
113. Hamann, L.G., Mani, N.S., Davis, R.L., Wang, X.N., Marschke, K.B. and Jones, T.K. (1999) Discovery of a potent, orally active, nonsteroidal androgens receptor agonist: 4-ethyl-1,2,3,4-tetrahydro-6-(trifluoromethyl)-8-pyridono[5,6-g]-quinoline (LG121071). Journal of Medicinal Chemistry, 42, 210-212.
114. Ligand Pharmaceuticals, Inc., US 6,017,924 (2000).
115. Ligand Pharmaceuticals, Inc., WO 2002/068427.
116. Ligand Pharmaceuticals, Inc., US 7,026,484 (2007).
117. Higuchi, R.I., Zhi, L., Edwards, J.P., Caferro, T.R., Ringgenberg, J.D., West, S.J., Kong, J.W., Hamann, L.G., Arienti, K.L., Cummings, M.L., Wu, M., Tegley, C.M., Jones, T.K., Lopez, F.J., Marschke, K.B. and Schrader, W.T. (20-24 August 2000) Potent, nonsteroidal androgens receptor modulators based on 2-quinolinone scaffolds: a platform for selective androgens receptor modulators (SARMs), 220th American Chemical Society National Meeting, abstract MEDI 5.
118. Mohler, M.L., Nair, V.A., Hwang, D.J., Rakov, I.M., Patil, R. and Miller, D.D. (2005) Nonsteroidal tissue selective androgens receptor modulators: a promising class of clinical candidates. Expert Opinion on Therapeutic Patents, 15, 1565-1585.
119. Buijsman, R.C., Hermkens, P.H., van Rijn, R.D., Stock, H.T. and Teerhuis, N.M. (2005) Non-steroidal steroid receptor modulators. Current Medicinal Chemistry, 12, 1017-1075.
120. Ligand Pharmaceuticals, Inc., US 6,667,313 (2003).
121. Ligand Pharmaceuticals, Inc., US 6,462,038 (2002).
122. Ligand Pharmaceuticals, Inc., US 6,566,372 (2003).
123. Miner, J.N., Burnett, K., Chang, W. et al. (21 September 2005) Steroid receptor modulators: approaches to selectivity for androgens receptor, Tissue-Selective Nuclear Receptor Symposia, Keystone Meeting.
124. van Oeveren, A., Motamedi, M., Martinborough, E., Zhao, S., Shen, Y., West, S., Chang, W., Kallel, A., Marschke, K.B., Lopez, F.J., Negro-Vilar, A. and Zhi, L. (2007) Novel selective androgens receptor modulators: SAR studies on 6-bisalkylamino-2-quinolinones. Bioorganic & Medicinal Chemistry Letters, 17, 1527-1531.
125. van Oeveren, A., Pio, B.A., Tegley, C.M., Higuchi, R.I., Wu, M., Jones, T.K., Marschke, K.B., Negro-Vilar, A. and Zhi, L. (2007) Discovery of an androgens receptor modulator pharmacophore based on 2-quinolinones. Bioorganic & Medicinal Chemistry Letters, 17, 1523-1526.
126. van Oeveren, A., Motamedi, M., Mani, N.S., Marschke, K.B., Lopez, F.J., Schrader, W.T., Negro-Vilar, A. and Zhi, L. (2006) Discovery of 6-N,N-bis(2,2,2-trifluoroethyl)amino-4-trifluoromethylquinolin-2(1H)-one as a novel selective androgens receptor modulator. Journal ofMedicinal Chemistry, 49, 6143-6146.
127. Wang, F., Liu, X.Q., Li, H., Liang, K.N., Miner, J.N., Hong, M., Kallel, E.A., van Oeveren, A., Zhi, L. and Jiang, T. (2006) Structure of the ligand-binding domain (LBD) of human androgens receptor in complex with a selective modulator LGD2226. Acta Crystallographica Section F: Structural Biology and Crystallization Communications, 62, 1067-1071.
128. Miner, J.N., Chang, W., Chapman, M.S., Finn, P.D., Hong, M.H., Lopez, F.J., Marschke, K.B., Rosen, J., Schrader, W., Turner, R., van Oeveren, A., Viveros, H., Zhi, L. and Negro-Vilar, A. (2007) An orally active selective androgens receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology, 148, 363-373.
129. Chang, W.Y., Vajda, E.G., Burnett, K., Talaoc, E.C., Mais, D.E., Marschke, K., Lopez, F.J., Viveros, O.H., Shen, Y., Martinborough, E., Hudson, A., Zhi, L. and Negro-Vilar, A. (15-19 September 2006) LGD2941 is a potent, orallyavailable selective androgens receptor modulator (SARM) with superior activity in bone and muscle in male rats, 28th Annual Meeting of the American Society for Bone and Mineral Research, abstract M388.
130. DeManno, D., Miller, G., Vajda, E., Gunawardhana, L., Niefhoff, M. and Weinbauer, G.F. (15-19 September 2006) LGD2941, an orally-available, nonsteroidal selective androgens receptor modulator (SARM) stimulates bone and muscle growth in male monkeys, 28th Annual Meeting of the American Society for Bone and Mineral Research, abstract M389.
131. Vajda, E., Chang, W.Y., Talaoc, E.C., Griffiths, K., Burnett, K., Marschke, K., Mais, D.E., Viveros, O.H., Shen, Y., Martinborough, E., Zhi, L. and Negro-Vilar, A. (15-19 September 2006) LGD2941 is an orally-available, nonsteroidal selective androgens receptor modulator (SARM) with superior bone activity in female rats, 28th Annual Meeting of the American Society for Bone and Mineral Research, abstract F400.
132. Pfizer, Inc., US 2005/004367.
133. Pfizer, Inc., WO 2004/072043.
134. Pfizer, Inc., US 2005/137228.
135. Merck & Co., Inc., US 7,196,076.
136. Merck & Co., Inc., WO 2003/077919.
137. Merck & Co., Inc., US 2004/0235808.
138. Merck & Co., Inc., WO 2004/0100874.
139. Merck & Co., Inc., WO 2006/0026196.
140. Merck & Co., Inc., WO 2005/0005606.
141. Merck & Co., Inc., WO 2005/009949.
142. Merck & Co., Inc., WO 2005/099707.
143. Merck & Co., Inc., US 2006/0258661.
144. Merck & Co., Inc., US 2006/0241107.
145. Merck & Co., Inc., WO 2005/0025579.
146. Merck & Co., Inc., WO 2005/004807.
147. Dankulich, W.P., Mitchell, H.J., Prueksaritanont, T., Schmidt, A., Vogel, R.L., Bai, C., McElwee-Witmer, S., Chen, F., Zhang, H.Z., Leu, C.T., Kimmel, D., Pennypacker, B., Masarachia, P., Pun, S., Scafonas, A., Adamski, S. and Meissner, R.S. (25-29 March 2007) 17-Arylcarbamidomethyl-4-azasteroids as selective androgens receptor modulators, 233rd American Chemical Society National Meeting, abstract MEDI 203.
148. Ortho-McNeil Pharmaceutical, Inc., US 6,858,621, (2005).
149. Kaken Pharmaceutical Co., Ltd, JP 2003/073374.
150. Kaken Pharmaceutical Co., Ltd, US 6,777,427, (2004).
151. Hanada, K., Furuya, K., Yamamoto, N., Nejishima, H., Ichikawa, K., Nakamura, T., Miyakawa, M., Amano, S., Sumita, Y. and Oguro, N. (2003) Bone anabolic effects of S-40503, a novel nonsteroidal selective androgens receptor modulator (SARM), in rat models of osteoporosis. Biological & Pharmaceutical Bulletin, 26, 1563-1569.
152. Kaken Pharmaceutical Co., Ltd, EP 1221439, (2001).
153. Kaken Pharmaceutical Co., Ltd, WO 2004/013104 (in Japanese).
154. Kaken Pharmaceutical Co., Ltd, WO 2004/000816 (in Japanese).
155. De Marzo, A.M., Platz, E.A., Sutcliffe, S., Xu, J., Gronberg, H., Drake, C.G., Nakai, Y., Isaacs, W.B. and Nelson, W.G. (2007) Inflammation in prostate carcinogenesis. Nature Reviews Cancer, 7, 256-269.
156. Kaken Pharmaceutical Co., Ltd, WO 2004/000816 (in Japanese).
157. Pfizer Products Inc., WO 2005/108351.
158. Ke, H.Z., Crawford, D.T., Qi, H. et al. (23-27 September 2005) Differential effects of 5α-dihydrotestosterone (DHT) and a novel selective androgen receptor modulator (SARM) on prostate and bone in intact and orchidectomized (ORX) male rats, 27th Annual Meeting of the American Society for Bone and Mineral Research, abstract M395.
159. Ke, H.Z., Crawford, D.T., Oi, H. et al. (1-5 October 2004) A novel, nonsteroidal selective androgens receptor modulator (SARM) increases periosteal bone formation and inhibits trabecular bone turnover in aged intact and orchidectomized male rats, 26th Annual Meeting of the American Society for Bone and Mineral Research, abstract 1216.
160. Ligand Pharmaceuticals, Inc., WO 2005/090282.
161. Ligand Pharmaceuticals, Inc., WO 2005/090282.
162. Karo Bio AB, WO 2005/042464.
163. Press release, (12 September 2006) Radius and Karo Bio announce licensing agreement for novel SARM compounds, http://www.radiuspharm.com.
164. GlaxoSmithKline, Inc., US 2006/0148893.
165. GlaxoSmithKline, Inc., WO2005/000795.
166. GlaxoSmithKline, Inc., WO2005/085185.
167. (Glaxo)SmithKlineBeecham Corp., WO 2006/133216.
168. GlaxoSmithKline, Inc., US 2006/0142387.
169. Trump, R.P., Blanc, J.B., Stewart, E.L., Brown, P.J., Caivano, M., Gray, D.W., Hoekstra, W.J., Willson, T.M., Han, B. and Turnbull, P. (2007) Design and synthesis of an array of selective androgens receptor modulators. Journal of Combinatorial Chemistry, 9, 107-114.
170. Han, B., Triantafillou, J.A., Shen, Y., Xu, T., Scates, P., Stimpson, S.A. and Turnbull, P.S. (2-5 June 2007) Pharmacological profiles of GSK2420A, a novel nonsteroidal selective androgens receptor modulator (SARM), Endocrine Society 89th Annual Meeting, abstract P1-623.
171. Janssen Pharmaceutica NV, US 2005/250740.
172. Janssen Pharmaceutica NV, US 2005/245485.
173. Johnson & Johnson, US 2006/0116412.
174. Johnson & Johnson, US 2006/0111402.
175. Ng, R.A., Guan, J., Alford, V.C., Jr, Lanter, J.C., Allan, G.F., Sbriscia, T., Lundeen, S.G. and Sui, Z. (2007) 2-(2,2,2-Trifluoroethyl)-5,6-dichlorobenzimidazole derivatives as potent androgens receptor antagonists. Bioorganic & Medicinal Chemistry Letters, 17, 955-958.
176. Ng, R.A., Lanter, J.C., Alford, V.C., Allan, G.F., Sbriscia, T., Lundeen, S.G. and Sui, Z. (2007) Synthesis of potent and tissueselective androgens receptor modulators (SARMs): 2-(2,2,2)-trifluoroethylbenzimidazole scaffold. Bioorganic & Medicinal Chemistry Letters, 17, 1784-1787.
177. Zhang, X., Li, X., Allan, G.F., Sbriscia, T., Linton, O., Lundeen, S.G. and Sui, Z. (2007) Serendipitous discovery of novel imidazolopyrazole scaffold as selective androgens receptor modulators. Bioorganic &Medicinal Chemistry Letters, 17, 439-443.
178. Allan, G., Lai, M.T., Sbriscia, T., Linton, O., Haynes-Johnson, D., Bhattacharjee, S., Dodds, R., Fiordeliso, J., Lanter, J., Sui, Z. and Lundeen, S. (2007) A selective androgens receptor modulator that reduces prostate tumor size and prevents orchidectomy-induced bone loss in rats. The Journal of Steroid Biochemistry and Molecular Biology, 103, 76-83.
179. Zhang, X., Allan, G.F., Sbriscia, T., Linton, O., Lundeen, S.G. and Sui, Z. (2006) Synthesis and SAR of novel hydantoin derivatives as selective androgens receptor modulators. Bioorganic & Medicinal Chemistry Letters, 16, 5763-5766.
180. Zhang, X., Li, X., Allan, G.F., Musto, A., Lundeen, S.G. and Sui, Z. (2006) Discovery of indole-containing tetracycles as a new scaffold for androgens receptor ligands. Bioorganic & Medicinal Chemistry Letters, 16, 3233-3237.
181. Balog, A., Salvati, M.E., Shan, W.,Mathur, A., Leith, L.W., Wei, D.D., Attar, R.M., Geng, J., Rizzo, C.A., Wang, C., Krystek, S.R., Tokarski, J.S., Hunt, J.T., Gottardis, M. and Weinmann, R. (2004) The synthesis and evaluation of [2.2.1]-bicycloazahydantoins as androgens receptor antagonists. Bioorganic & Medicinal Chemistry Letters, 14, 6107-6111.
182. Hamann, L.G., Manfredi, M.C., Sun, C., Krystek, S.R., Jr, Huang, Y., Bi, Y., Augeri, D.J., Wang, T., Zou, Y., Betebenner, D.A., Fura, A., Seethala, R., Golla, R., Kuhns, J.E., Lupisella, J.A., Darienzo, C.J., Custer, L.L., Price, J.L., Johnson, J.M., Biller, S.A., Zahler, R. and Ostrowski, J. (2007) Tandem optimization of target activity and elimination of mutagenic potential in a potent series of N-aryl bicyclic hydantoin-based selective androgens receptor modulators. Bioorganic & Medicinal Chemistry Letters, 17, 1860-1864.
183. Sun, C., Robl, J.A., Wang, T.C., Huang, Y., Kuhns, J.E., Lupisella, J.A., Beehler, B.C., Golla, R., Sleph, P.G., Seethala, R., Fura, A., Krystek, S.R., Jr, An, Y., Malley, M.F., Sack, J.S., Salvati, M.E., Grover, G.J., Ostrowski, J. and Hamann, L.G. (2006) Discovery of potent, orally-active, and muscle-selective androgens receptor modulators based on an N-aryl-hydroxybicyclohydantoin scaffold. Journal of Medicinal Chemistry, 49, 7596-7599.
184. Ostrowski, J., Kuhns, J.E., Lupisella, J.A., Manfredi, M.C., Beehler, B.C., Krystek, S.R., Jr, Bi, Y., Sun, C., Seethala, R., Golla, R., Sleph, P.G., Fura, A., An, Y., Kish, K.F., Sack, J.S., Mookhtiar, K.A., Grover, G.J. and Hamann, L.G. (2007) Pharmacological and X-ray structural characterization of a novel selective androgens receptor modulator: potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology, 148, 4-12.
185. Wilson, E.M. (2007) Muscle-bound? A tissue-selective nonsteroidal androgens receptor modulator. Endocrinology, 148, 1-3.
186. Eli Lilly & Co., WO 2006/124447.
187. Acadia Pharmaceuticals, Inc., WO 2005/115361.
188. Acadia Pharmaceuticals, Inc., US 2006/0160845.
189. Press release, (21 February 2006) Acadia Pharmaceuticals announces advancements in two preclinical programs, http://www.acadia-pharm.com.
190. Takeda Pharmaceuticals of North America, Inc., US 2006/0106067.
191. Takeda Pharmaceutical Co., Ltd, WO 2004/016576.
192. Akzo Nobel NV, WO 2004/041782.
193. Akzo Nobel NV, WO 2005/102998.
194. Higuchi, R.I., Arienti, K.L., Lopez, F.J., Mani, N.S., Mais, D.E., Caferro, T.R., Long, Y.O., Jones, T.K., Edwards, J.P., Zhi, L., Schrader, W.T., Negro-Vilar, A. and Marschke, K.B. (2007) Novel series of potent, nonsteroidal, selective androgens receptor modulators based on 7H-[1,4]oxazino[3,2-g]quinolin-7-ones. Journal of Medicinal Chemistry, 50, 2486-2496.
195. Bohl, C.E., Miller, D.D., Chen, J., Bell, C.E. and Dalton, J.T. (2005) Structural basis for accommodation of nonsteroidal ligands in the androgens receptor. The Journal of Biological Chemistry, 280, 37747-37754.
196. Sack, J.S., Kish, K.F., Wang, C., Attar, R.M., Kiefer, S.E., An, Y., Wu, G.Y., Scheffler, J.E., Salvati, M.E., Krystek, S.R., Jr, Weinmann, R. and Einspahr, H.M. (2001) Crystallographic structures of the ligand-binding domains of the androgens receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone. Proceedings of the National Academy of Sciences of the United States of America, 98, 4904-4909.
197. Pereira de Jesus-Tran, K., Cote, P.L., Cantin, L., Blanchet, J., Labrie, F. and Breton, R. (2006) Comparison of crystal structures of human androgens receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Science:APublication of the Protein Society, 15, 987-999.
198. Bohl, C.E., Wu, Z., Miller, D.D., Bell, C.E. and Dalton, J.T. (2007) Crystal structure of the T877A human androgens receptor ligand-binding domain complexed to cyproterone acetate provides insight for ligand-induced conformational changes and structure-based drug design. The Journal of Biological Chemistry, 282, 13648-13655.
199. Gao, W. and Dalton, J.T. (2007) Ockhams razor and selective androgens receptor modulators (SARMs): are we overlooking the role of 5α-reductase? Molecular Interventions, 7, 10-13.
200. Allan, G.F. and Sui, Z. (2003) Therapeutic androgens receptor ligands. Nuclear Receptor Signaling, 1, e009.
201. Ho, S.M. (2003) Estrogen, progesterone and epithelial ovarian cancer. Reproductive Biology and Endocrinology, 1, 73.
202. Ho, S.M. (2004) Estrogens and antiestrogens:key mediators of prostate carcinogenesis and new therapeutic candidates. Journal of Cellular Biochemistry, 91, 491-503.
203. Smith, C.L. and O'Malley, B.W. (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews, 25, 45-71.
204. Jongen, V.H., Hollema, H., Van Der Zee, A.G. and Heineman, M.J. (2006) Aromatase in the context of breast and endometrial cancer. A review. Minerva Endocrinologica, 31, 47-60.
205. Wright, A.S., Douglas, R.C., Thomas, L.N., Lazier, C.B. and Rittmaster, R.S. (1999) Androgen-induced regrowth in the castrated rat ventral prostate: role of 5α-reductase. Endocrinology, 140, 4509-4515.
206. Allan, G.F., Leng, X., Tsai, S.Y., Weigel, N.L., Edwards, D.P., Tsai, M.J. and O'Malley, B.W. (1992) Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. The Journal of Biological Chemistry, 267, 19513-19520.
207. Allan, G.F., Tsai, S.Y., Tsai, M.J. and O'Malley, B.W. (1992) Ligand-dependent conformational changes in the progesterone receptor are necessary for events that follow DNA binding. Proceedings of the National Academy of Sciences of the United States of America, 89, 11750-11754.
208. Bebermeier, J.H., Brooks, J.D., DePrimo, S.E., Werner, R., Deppe, U., Demeter, J., Hiort, O. and Holterhus, P.M. (2006) Cellline and tissue-specific signatures of androgens receptor-coregulator transcription. Journal of Molecular Medicine (Berlin, Germany), 84, 919-931.
209. Jaber, B.M., Mukopadhyay, R. and Smith, C.L. (2004) Estrogen receptor-α interaction with the CREB binding protein coactivator is regulated by the cellular environment. Journal of Molecular Endocrinology, 32, 307-323.
210. Horner-Glister, E., Maleki-Dizaji, M., Guerin, C.J., Johnson, S.M., Styles, J. and White, I.N. (2005) Influence of oestradiol and tamoxifen on oestrogen receptors-α and -β protein degradation and nongenomic signalling pathways in uterine and breast carcinoma cells. Journal of Molecular Endocrinology, 35, 421-432.
211. Chang, C.Y. and McDonnell, D.P. (2002) Evaluation of ligand-dependent changes in AR structure using peptide probes. Molecular Endocrinology, 16, 647-660.
212. Chang, C., Norris, J.D., Gron, H., Paige, L.A., Hamilton, P.T., Kenan, D.J., Fowlkes, D. and McDonnell, D.P. (1999) Dissection of the LXXLL nuclear receptor-coactivator interaction motif using combinatorial peptide libraries:discovery of peptide antagonists of estrogen receptors α and β. Molecular and Cellular Biology, 19, 8226-8239.
213. Kazmin, D., Prytkova, T., Cook, C.E., Wolfinger, R., Chu, T.M., Beratan, D., Norris, J.D., Chang, C.Y. and McDonnell, D.P. (2006) Linking ligand-induced alterations in androgens receptor structure to differential gene expression: a first step in the rational design of selective androgens receptor modulators. Molecular Endocrinology, 20, 1201-1217.
214. Baek, S.H., Ohgi, K.A., Nelson, C.A., Welsbie, D., Chen, C., Sawyers, C.L., Rose, D.W. and Rosenfeld, M.G. (2006) Ligand-specific allosteric regulation of coactivator functions of androgens receptor in prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 103, 3100-3105.
215. McInerney, E.M., Rose, D.W., Flynn, S.E., Westin, S., Mullen, T.M., Krones, A., Inostroza, J., Torchia, J., Nolte, R.T., Assa-Munt, N., Milburn, M.V., Glass, C.K. and Rosenfeld, M.G. (1998) Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. Genes and Development, 12, 3357-3368.
216. Chang, C.Y. and McDonnell, D.P. (2005) Androgen receptor-cofactor interactions as targets for new drug discovery. Trends in Pharmacological Sciences, 26, 225-228.
217. Heinlein, C.A. and Chang, C. (2002) Androgen receptor (AR) coregulators: an overview. Endocrine Reviews, 23, 175-200.
218. Heery, D.M., Kalkhoven, E., Hoare, S. and Parker, M.G. (1997) A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature, 387, 733-736.
219. Shiau, A.K., Barstad, D., Loria, P.M., Cheng, L., Kushner, P.J., Agard, D.A. and Greene, G.L. (1998) The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell, 95, 927-937.
220. Fujimoto, N., Yeh, S., Kang, H.Y., Inui, S., Chang, H.C., Mizokami, A. and Chang, C. (1999) Cloning and characterization of androgens receptor coactivator, ARA55, in human prostate. The Journal of Biological Chemistry, 274, 8316-8321.
221. Kang, H.Y., Yeh, S., Fujimoto, N. and Chang, C. (1999) Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgens receptor. The Journal of Biological Chemistry, 274, 8570-8576.
222. Guo, D., Zhang, H., Liu, L., Wang, L., Cheng, Y. and Qiao, Z. (2004) Testosterone influenced the expression of Notch1, Notch2 and Jagged1 induced by lipopolysaccharide in macrophages. Experimental and Toxicologic Pathology, 56, 173-179.
223. Kang, H.Y., Cho, C.L., Huang, K.L., Wang, J.C., Hu, Y.C., Lin, H.K., Chang, C. and Huang, K.E. (2004) Nongenomic androgens activation of phosphatidylinositol 3-kinase/Akt signaling pathway in MC3T3-E1 osteoblasts. Journal of Bone and Mineral Research, 19, 1181-1190.
224. Liu, L., Wang, L., Zhao, Y., Wang, Y., Wang, Z. and Qiao, Z. (2006) Testosterone attenuates p38 MAPK pathway during Leishmania donovani infection of macrophages. Parasitology Research, 99, 189-193.
225. Huber, D.M., Bendixen, A.C., Pathrose, P., Srivastava, S., Dienger, K.M., Shevde, N.K. and Pike, J.W. (2001) Androgens suppress osteoclast formation induced by RANKL and macrophage-colony stimulating factor. Endocrinology, 142, 3800-3808.
226. Dehm, S.M. and Tindall, D.J. (2006) Ligand-independent androgens receptor activity is activation function-2-independent and resistant to antiandrogens in androgens refractory prostate cancer cells. The Journal of Biological Chemistry, 281, 27882-27893.
227. Kousteni, S., Bellido, T., Plotkin, L.I., O'Brien, C.A., Bodenner, D.L., Han, L., Han, K., DiGregorio, G.B., Katzenellenbogen, J.A., Katzenellenbogen, B.S., Roberson, P.K., Weinstein, R.S., Jilka, R.L. and Manolagas, S.C. (2001) Nongenotropic, sex-nonspecific signaling through the estrogen or androgens receptors:dissociation from transcriptional activity. Cell, 104, 719-730.
228. Lutz, L.B., Jamnongjit, M., Yang, W.H., Jahani, D., Gill, A. and Hammes, S.R. (2003) Selective modulation of genomic and nongenomic androgens responses by androgens receptor ligands. Molecular Endocrinology, 17, 1106-1116.
229. Sundaram, K., Kumar, N. and Bardin, C.W. (1993) 7 α-methyl-nortestosterone (MENT): the optimal androgens for male contraception. Annals of Medicine, 25, 199-205.
230. Gao, W., Kim, J. and Dalton, J.T. (2006) Pharmacokinetics and pharmacodynamics of nonsteroidal androgens receptor ligands. Pharmaceutical Research, 23, 1641-1658.
231. Jockenhovel, F. (2004) Testosterone therapy - what, when and to whom? Aging Male, 7, 319-324.
232. Mazer, N., Bell, D., Wu, J., Fischer, J., Cosgrove, M. and Eilers, B. (2005) Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men. Journal of Sexual Medicine, 2, 213-226.
233. Press release, (17 April 2007) GTx announces Ostarine™ improved insulin resistance among elderly patients in a recently completed phase II clinical trial, http://www.gtxinc.com.
234. Langer, C.J., Hoffman, J.P. and Ottery, F.D. (2001) Clinical significance of weight loss in cancer patients: rationale for the use of anabolic agents in the treatment of cancer-related cachexia. Nutrition, 17 (1 Suppl), S1-S20.
235. Kurella, M., Ireland, C., Hlatky, M.A., Shlipak, M.G., Yaffe, K., Hulley, S.B. and Chertow, G.M. (2004) Physical and sexual function in women with chronic kidney disease. American Journal of Kidney Diseases, 43, 868-876.
236. Segal, S., Narayanan, R. and Dalton, J.T. (2006) Therapeutic potential of the SARMs: Revisiting the androgens receptor for drug discovery. Expert Opin Invest Drugs, 15, 377-387.
237. Johansen, K.L. (1999) Physical functioning and exercise capacity in patients on dialysis. Advances in Renal Replacement Therapy, 6, 141-148.
238. Stuart, M. and Weinrich, M. (2004) Integrated health system for chronic disease management: lessons learned from France. Chest, 125, 695-703.
239. Maltais, F. and Debigare, R. (2003) Biology of muscle impairment in COPD. Monaldi Archives for Chest Disease, 59, 338-341.
240. Laghi, F., Antonescu-Turcu, A., Collins, E., Segal, J., Tobin, D.E., Jubran, A. and Tobin, M.J. (2005) Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. American Journal of Respiratory and Critical Care Medicine, 171, 728-733.
241. Leveille, S.G. (2004) Musculoskeletal aging. Current Opinion in Rheumatology, 16, 114-118.
242. Baumgartner, R.N., Koehler, K.M., Gallagher, D., Romero, L., Heymsfield, S.B., Ross, R.R., Garry, P.J. and Lindeman, R.D. (1998) Epidemiology of sarcopenia among the elderly in New Mexico. American Journal of Epidemiology, 147, 755-763.
243. Muhlberg, W. and Sieber, C. (2004) Sarcopenia and frailty in geriatric patients: implications for training and prevention. Zeitschrift fur Gerontologie und Geriatrie, 37, 2-8.
244. Lynch, G.S. (2004) Emerging drugs for sarcopenia: age-related muscle wasting. Expert Opinion on Emerging Drugs, 9, 345-361.
245. Tanaka, Y., Nakayamada, S. and Okada, Y. (2005) Osteoblasts and osteoclasts in bone remodeling and inflammation. Current Drug Targets Inflammation & Allergy, 4, 325-328.
246. Greenblatt, D. (2005) Treatment of postmenopausal osteoporosis. Pharmacotherapy, 25, 574-584.
247. Shrader, S.P. and Ragucci, K.R. (2005) Parathyroid hormone (1-84) and treatment of osteoporosis. Annals of Pharmacotherapy, 39, 1511-1516.
248. Chen, J., Kim, J. and Dalton, J.T. (2005) Discovery and therapeutic promise of selective androgens receptor modulators. Molecular Interventions, 5, 173-188.
249. Soule, S.G., Conway, G., Prelevic, G.M., Prentice, M., Ginsburg, J. and Jacobs, H.S. (1995) Osteopenia as a feature of the androgens insensitivity syndrome. Clinical Endocrinology, 43, 671-675.
250. Wakley, G.K., Schutte, H.D., Jr, Hannon, K.S. and Turner, R.T. (1991) Androgen treatment prevents loss of cancellous bone in the orchidectomized rat. Journal of Bone and Mineral Research, 6, 325-330.
251. Mason, R.A. and Morris, H.A. (1997) Effects of dihydrotestosterone on bone biochemical markers in sham and oophorectomized rats. Journal of Bone and Mineral Research, 12, 1431-1437.
252. Goulding, A. and Gold, E. (1993) Flutamide-mediated androgens blockade evokes osteopenia in the female rat. Journal of Bone and Mineral Research, 8, 763-769.